30Jan 2017

ROLE OF S100P AS A NEW PROGNOSTIC MARKER IN WOMEN WITH METASTATIC BREAST CANCER AND ITS CORRELATION WITH BCL2 AND BAX EXPRESSION.

  • Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University.
  • Clinical Pathology Department, Faculty of Medicine, Zagazig University.
  • Medical Oncology Department, Faculty of Medicine, Zagazig University.
  • Pathology Department, Faculty of Medicine, Zagazig University.
  • General surgery Department, Faculty of Medicine, Zagazig University.
Crossref Cited-by Linking logo

Plum Print visual indicator of research metrics
  • Captures
    • Readers: 2
see details

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background; Breast cancer is the commonest malignancy and the second cause of cancer-related death in women worldwide. Understanding the underlying molecular biology of breast cancer allow better management to decrease its mortality. The S100 P is a member of S100 family of Ca2+ -binding proteins. Apoptosis is a physiologic mechanism of cell death that has been shown to play important role in cancer development. Bcl-2 is an anti-apoptotic gene that has the ability to block apoptotic signals, while Bax is another member of the Bcl-2 family that has an apoptosis-stimulating function. The aims of our study were to elucidate the prognostic role of S100P, bcl2 and bax in breast cancer, clarify the relation between their expressions and the prognosis of that type of cancer. Method: The plasma S100P levels ( by ELISA) and expressions of bcl2& bax ( by Immunohistochemistry) were evaluated in 90 women; 70 metastatic breast cancer patients (MBC), 12 primary breast cancer patients (PBC) and 8 healthy controls, thenwe assessed the prognostic value of S100P, bax, bcl2 in breast cancer patients. RESULTS: the plasma S100P level was nearly the same for PBC patients and controls, but was higher than that of MBC patients (p<0.001). There is significant correlations between the level of S100P with capsular invasion (p =0.018), stage, bcl2 and bax (P <0.001). In MBC there is a significant association between elevation of S100P level, number and site of metastasis (P<0.001). Bcl2 expressions in breast cancer patients had negative significant correlations with grade (P< 0.001), ki67 (P< 0.021), molecular subtype (P< 0.050), stage (P <0.001), and S100p (P<0.05), also its expression in MBC patients was statistically significant with number of metastasis (P=0.014). Bax high expression is statistically significant with grade (P=0.003), stage (P<0.001), ER (P<0.010), PR (P<0.023), Her-2 neu (P<0.002), but in MBC patients it is statistically significant with the site of metastasis (P=0.003). The plasma of S100P level is significantly correlated with response to therapy, disease progression (P<0.001) and Overall survival (OS) of patients (P=0.014). Bcl2 expression is significantly correlated with response to therapy (P <0.001), disease progression (P 0.004) and OS (P=0.014). Conclusion: S100P, BCL2 and bax are promising prognostic markers in breast cancer patients

  1. Siegel R, Ma J, Zou Z, et al (2014); Cancer statistics. CA: A Cancer J Clin. 64:9?29.
  2. Amal S. Ibrahim, Hussein M. Khaled, et al (2014):- Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. Journal of Cancer Epidemiology, Volume , Article ID 437971, 18
  3. Dakhel S, Padilla L, Adan J, et al (2014):-S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Citation:Oncogenesis??3, 92; doi:10.1038/oncsis.2014.7
  4. Peng C ,Chen H ,?Wallwiener M?(2016):-Plasma S100P level as a novel prognostic marker of metastatic breast cancer.Breast Cancer Res Treat; 157(2):329-38.
  5. Ohuchida K, Mizumoto K, Egami T, et al (2006). S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 12(18):5411?5416.
  6. Li Y, St John MA, Zhou X,et al (2004):- Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 10(24):8442?8450.
  7. Thompson CB (1995):- Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456?1462
  8. Wyllie AH (1987):- Apoptosis: cell death in tissue regulation. J Pathol ; 153:313?316.
  9. Kerr JF, Winterford CM and Harmon BV (1994):- Apoptosis. Its significance in cancer and cancer therapy. Cancer. ; 73:2013? 2026.
  10. Meterissian SH (1997):- Apoptosis: its role in the progression of and chemotherapy for carcinoma. J Am Coll Surg , 184:658-666.
  11. Cleary ML, Smith SD and Sklar J (1986):- Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell; 47:19?28.
  12. Adams JM and Cory S (1998):-The Bcl-2 protein family: arbiters of cell survival. Science; 281:1322?1326.
  13. Edge SB and Compton CC. (2010) :-The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.Ann Surg Oncol. Jun; 17(6):1471-4. doi: 10.1245/s10434-010-0985-4.
  14. Elston CW(2002) :- Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
  15. Hsu SM, Raine L and Fanger H (1981):- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J HistochemCytochem ; 29:577-580
  16. Zhang G-J, Kimijima I, Abe R, et al(1997):-Correlation between the expression of apoptosis-related bcl-2 and p53 oncoprotein and the carcinogenesis and progression of breast cancer. Clin Cancer Res; 3:2329?
  17. Veronesel S, Francesco A. Mauri I, et al(1998): Bax immunohistochemical expression in breast cancer.A study with long term follow up . J. Cancer (Pred. Oncol.): 79, 13?18 .
  18. Breast Cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/ (Accessed on March 04, 2013).
  19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005):- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet ; 365:1687.
  20. Chia SK, Speers CH, D'yachkova Y, et al (2007):- The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer ; 110:973.
  21. Dafni U, Grimani I, Xyrafas A, et al.(2010):- Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat ; 119:621.
  22. Prica F, RadonT,?Cheng Y,et al (2016):- The life and works of S100P - from conception to cancer. .?Am J Cancer Res. 2016; 6(2): 562?576.
  23. Donato R (2001):- S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.?Int J Biochem Cell Biol ;33:637?668.
  24. Parkkila S, Pan PW, Ward A,et al (2008):- The calcium binding protein S100P in normal and malignant human tissues.?BMC Clin Pathol ;8:2.
  25. Ciocca DR and Calderwood SK (2005):- Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.?Cell Stress Chaperones ;10:86?103.
  26. Johnson M, Sharma M, Henderson BR (2009):- IQGAP1 regulation and roles in cancer.?Cell Signal ;21:1471?1478.
  27. Wang Q, He Z, Gao J, et al (2008):-. S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.Cancer Lett.?;272:277?284.
  28. Zhao X, Bai Z, Wu P, et al (2013):-. S100P enhances the chemosensitivity of human gastric cancer cell lines.Cancer Biomark.;13:1?10.
  29. Tong XM, Lin XN, Song T, et al (2010):- Calcium-binding protein S100P is highly expressed during the implantation window in human endometrium.?Fertil Steril; 94:1510?1518.
  30. Maciejczyk A, Lacko A, Ekiert M,et al? (2013):-Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.?Histol Histopathol ;28:513?52476
  31. Liu S, Edgerton SM, Moore DH, et al (2001) :- Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res, 7: 1716?1723
  32. Ioachim EE, Malamou-Mitsi V, Kamina SA, et al(2000):-Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res, 20: 4221?4225.
  33. Bargou RC, Daniel PT, Mapara MY, et al (1995) :-Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer, 60: 854?859.
  34. Gee JM, Robertson JF, Ellis IO,et al (1994) :-Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 59: 619?628.
  35. Zhang GJ, Kimijima I, Abe R, et al (1998):- Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res, 18: 1989?1998
  36. Rochaix P, Krajewski S, Reed JC, et al(1999):- In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol, 187: 410?415.
  37. Berardo MD, Elledge RM, de Moor C, et al(1998) :-Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer, 82: 1296?1302.
  38. Honma1N, Horii R, Ito Y, et al (2015):-Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer , 15:698 DOI 10.1186/s12885-015-1686-y
  39. Dawson S,? Makretsov N,? Blows FM, et al (2010) :- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received .British Journal of Cancer ;103, 668 ? 675
  40. Cory S, Huang DC, Adams JM, et al (2003) :- The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590?8607
  41. Silvestrini R, Benini E, Veneroni S,et al (1996) :-P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol,14: 1604?1610.
  42. Lipponen P, Pietilainen T, Kosma VM, et al(1995):- A poptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177: 49?55.
  43. Pietenpol JA, Papadopoulos N, Markowitz S, et al (1994) :-Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 54: 3714?3717
  44. Wang TT and Phang JM (1995):- Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487?2489
  45. Krajewski S, Thor AD, Edgerton SM , et al (1997): Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res , Feb; 3(2): 199-208.
  46. Krajewski S, Blomqvist C, Franssila K , et al (1995): Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res ; 55(19): 4471-78
  47. Pluta P and Smolewsk P? (2011): Significance of Bax expression in breast cancer patients. Polish Journal of Surgery , 83, 10, 549?553.

[Lobna A. Abdelaziz, Hoda F. Ebian,Shereen El Shorbagy, Rham Z.Ahmed, Ola A. Harb, Mariem A. Elfeky, Mohammed E.Eraki and Loay M. Gertallah. (2017); ROLE OF S100P AS A NEW PROGNOSTIC MARKER IN WOMEN WITH METASTATIC BREAST CANCER AND ITS CORRELATION WITH BCL2 AND BAX EXPRESSION. Int. J. of Adv. Res. 5 (Jan). 1849-1868] (ISSN 2320-5407). www.journalijar.com

Lobna Abdelaziz Abdelaziz
Lobna A. Abdelaziz

DOI:

Article DOI: 10.21474/IJAR01/2956      
DOI URL: https://dx.doi.org/10.21474/IJAR01/2956

Download Full Paper

Download PDF No. of Downloads: 20 | No. of Views: 111